A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis
Article first published online: 1 MAR 2004
Clinical & Experimental Allergy
Volume 34, Issue 4, pages 646–649, April 2004
How to Cite
Lee, D. K. C., Gray, R. D., Robb, F. M., Fujihara, S. and Lipworth, B. J. (2004), A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. Clinical & Experimental Allergy, 34: 646–649. doi: 10.1111/j.1365-2222.2004.1903.x
- Issue published online: 3 MAR 2004
- Article first published online: 1 MAR 2004
- Submitted 11 August 2003; revised 16 October 2003; accepted 28 November 2003
- adenosine monophosphate;
- nasal challenge;
- peak nasal inspiratory flow;
- perennial allergic rhinitis;
- petasites hybridus
Background There are presently no placebo-controlled data regarding the effects of butterbur (BB) on subjective and objective outcomes in patients with perennial allergic rhinitis.
Objective We performed a placebo-controlled evaluation of the effects of BB and fexofenadine (FEX) on subjective and objective outcomes in patients with perennial allergic rhinitis.
Methods Sixteen patients with perennial allergic rhinitis and house dust mite sensitization were randomized in double-blind cross-over fashion to receive for 1 week either BB 50 mg twice daily, FEX 180 mg once daily and placebo (PL) once daily, or PL twice daily. The peak nasal inspiratory flow (PNIF) response to adenosine monophosphate (AMP) challenge administered as a single 400 mg/mL dose was measured over a 60-min period after challenge, and domiciliary total nasal symptom score was recorded.
Results Pre-challenge values for mean±SEM PNIF (L/min) were not significantly different comparing all groups; BB (138±8), FEX (140±9), and PL (138±8). The maximum % PNIF fall from baseline after nasal AMP challenge was significantly attenuated (P<0.05) compared to PL (46±3), with BB (34±3) and FEX (39±3). The area under the 60-min time–response curve (%.min) was also significantly attenuated (P<0.05) compared to PL (1734±156), with BB (1052±258) and FEX (1194±161). There was also a significant reduction (P<0.05) in total nasal symptom score with BB (1.8±0.4) and FEX (1.8±0.4), compared to PL (2.8±0.5). There were no significant differences between BB and FEX for any outcomes.
Conclusion BB and FEX, in comparison to PL, were equally effective in attenuating the nasal response to AMP and in improving nasal symptoms, highlighting a potential role for BB in the treatment of allergic rhinitis.